Should I buy or sell Atossa Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATOS shares. View ATOS analyst ratings or view top-rated stocks .

What is Atossa Therapeutics' stock price target for 2024?

1 brokerages have issued 1 year price objectives for Atossa Therapeutics' stock. Their ATOS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 563.8% from the stock's current price. View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts .

How have ATOS shares performed in 2023?

Atossa Therapeutics' stock was trading at $0.5285 at the start of the year. Since then, ATOS shares have increased by 42.5% and is now trading at $0.7532. View the best growth stocks for 2023 here .

When is Atossa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ATOS earnings forecast .

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

When did Atossa Therapeutics' stock split?

Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?

8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com . Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO) , Alibaba Group (BABA) , Heat Biologics (HTBX) , Vaxart (VXRT) , Biocept (BIOC) , MannKind (MNKD) , Biopharmx (BPMX) , Daré Bioscience (DARE) , OPKO Health (OPK) and Nokia Oyj (NOK) .

Who are Atossa Therapeutics' major shareholders?

Atossa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.28%), Connor Clark & Lunn Investment Management Ltd. (0.11%), UBS Group AG (0.03%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Atossa Therapeutics?

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Atossa Therapeutics Stock Price, News & Analysis (NASDAQ:ATOS)

$0.75

+0.02 (+2.73%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.72
▼
$0.77
50-Day Range: $0.63
▼
$0.81
52-Week Range: $0.50
▼
$1.39

Volume: 191,714 shs
Average Volume: 274,561 shs
Market Capitalization: $94.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Atossa Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 563.8% Upside
$5.00 Price Target
Short Interest: Bearish
5.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.40
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.24) to ($0.26) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

725th out of 932 stocks

Pharmaceutical Preparations Industry

344th out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
Atossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Atossa Therapeutics has a forecasted upside of 563.8% from its current price of $0.75.
Amount of Analyst Coverage
Atossa Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.08% of the outstanding shares of Atossa Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Atossa Therapeutics has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Atossa Therapeutics has recently decreased by 4.21%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Atossa Therapeutics does not currently pay a dividend.
Dividend Growth
Atossa Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATOS.

3.0

News and Social Media Coverage

News Sentiment
Atossa Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Atossa Therapeutics this week, compared to 1 article on an average week.
Search Interest
9 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
9 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Atossa Therapeutics is held by insiders.
Percentage Held by Institutions
Only 12.74% of the stock of Atossa Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.24) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atossa Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atossa Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atossa Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Atossa Therapeutics Stock (NASDAQ:ATOS)

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

ATOS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATOS Stock News Headlines

December 8, 2023 | finance.yahoo.com

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

December 4, 2023 | proactiveinvestors.com

Atossa Therapeutics taps Arezoo Mirad for Senior Medical Director

December 10, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 4, 2023 | finance.yahoo.com

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

November 20, 2023 | finance.yahoo.com

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

November 13, 2023 | msn.com

Atossa Therapeutics GAAP EPS of -$0.05 beats by $0.02

November 13, 2023 | proactiveinvestors.com

Atossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3Q

November 13, 2023 | finance.yahoo.com

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

December 10, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 30, 2023 | proactiveinvestors.com

Atossa Therapeutics’ (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

October 17, 2023 | finance.yahoo.com

Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

October 11, 2023 | bizjournals.com

Atossa Therapeutics names finance lead after CFO's quick exit

October 11, 2023 | finance.yahoo.com

Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

September 18, 2023 | finance.yahoo.com

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

September 18, 2023 | finance.yahoo.com

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

September 8, 2023 | msn.com

Cantor Fitzgerald Initiates Coverage of Atossa Therapeutics (ATOS) with Overweight Recommendation

September 8, 2023 | msn.com

Atossa stock jumps 16% in wake of Cantor overweight rating

September 8, 2023 | markets.businessinsider.com

Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst

August 31, 2023 | msn.com

Atossa Therapeutics: Betting Big On Transforming Old Breast Cancer Care

August 31, 2023 | msn.com

Atossa Therapeutics (ATOS) Price Target Increased by 13.51% to 5.36

August 23, 2023 | proactiveinvestors.com

Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral Endoxifen

August 23, 2023 | finance.yahoo.com

Atossa Therapeutics backing Endoxifen in the fight against breast cancer

August 23, 2023 | proactiveinvestors.com

Atossa Therapeutics backing Endoxifen in the fight against...Atossa Therapeutics backing Endoxifen in the fight against breast...

August 15, 2023 | finance.yahoo.com

Q2 2023 Atossa Therapeutics Inc Earnings Call

August 14, 2023 | finance.yahoo.com

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 20, 2023 | msn.com

Atossa gains as Canada greenlights breast cancer trial

July 20, 2023 | finanznachrichten.de

Atossa Therapeutics, Inc.: Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

See More Headlines

Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/10/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ATOS
CUSIP: N/A
CIK: 1488039
Web: atossatherapeutics.com
Phone: (206) 588-0256
Fax: 206-430-1288
Employees: 11
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +563.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -24.80%
Return on Assets: -23.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 28.35
Quick Ratio: 28.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.93 per share
Price / Book: 0.81

Miscellaneous

Outstanding Shares: 125,300,000
Free Float: 115,530,000
Market Cap: $94.38 million
Optionable: Not Optionable
Beta: 1.21

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Steven C. Quay FCAP (Age 72)
M.D., Ph.D., Chairman, CEO & President
Comp: $1.14M
Ms. Heather Rees (Age 51)
SVP, Finance & Principal Accounting Officer
Ms. Delly Behen P.H.R.
Vice President of Administration & Human Resources
Mr. Eric Van Zanten
Vice President of Investor & Public Relations
Dr. Richard Graydon M.D.
Ph.D., Interim Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ATOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Atossa Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATOS shares.
View ATOS analyst ratings or view top-rated stocks.
What is Atossa Therapeutics' stock price target for 2024?: 1 brokerages have issued 1 year price objectives for Atossa Therapeutics' stock. Their ATOS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 563.8% from the stock's current price.
View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts.
How have ATOS shares performed in 2023?: Atossa Therapeutics' stock was trading at $0.5285 at the start of the year. Since then, ATOS shares have increased by 42.5% and is now trading at $0.7532.
View the best growth stocks for 2023 here.
When is Atossa Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ATOS earnings forecast.
How were Atossa Therapeutics' earnings last quarter?: Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.
When did Atossa Therapeutics' stock split?: Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?: 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.
What other stocks do shareholders of Atossa Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK).
Who are Atossa Therapeutics' major shareholders?: Atossa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.28%), Connor Clark & Lunn Investment Management Ltd. (0.11%), UBS Group AG (0.03%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Atossa Therapeutics?: Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ATOS) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial